ClinicalTrials.gg
RecruitingNCT07053969Updated Nov 12, 2025

The Effect Of Enamel Matrix Derivatives On Gingival Tissue Thickness

An interventional study of Enamel Matrix Derivative in Dental Implantation, Missing Teeth and Periodontitis, Adult, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to participants aged 18 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by The University of Texas Health Science Center at San Antonio · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Chronic Periodontitis with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Chronic Periodontitis · United States.

Planned enrollment
15th of 20
32 · median 53
Started
2025
the only one that year
No phase
11 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies in Chronic Periodontitis with a site in United States, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 22nd registered.

Chronic Periodontitis

378 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.

Browse Chronic Periodontitis studies →

Open to participants now

2 of the 22 studies in Chronic Periodontitis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Chronic Periodontitis with a site in United States, or all of them as a file.
02

Study summary

Scientists do research to answer important questions which might help change or improve the way we do things in the future.

The investigators know that using Enamel Matrix Derivatives results in thicker gum tissues around teeth. This study will test to see if using EMD around implants results in thicker gum tissues around implants.

Read the detailed description

The hypothesis of the study is that the addition of EMD under the gingival flap prior to suturing will result in increased mucosal tissue thickness and increased keratinized tissue width as compared to not using the EMD.

The EMD will be deposited under the mucosal flap during the second stage implant uncovering. After flap suturing, an intraoral scan will be obtained. This procedure will require approximately 5 - 10 minutes per patient. All patients will be followed up at 14 days for suture removal per standard of care and not as part of the study. All patients will be followed up at one and three months per standard of care during which visits they will undergo an intraoral scan to allow evaluation of soft tissue dimensions. This is research only procedure that is expected to add 5 - 10 minutes to the regular postoperative visit. Study participation will be completed at the 3-month visit.

03

Conditions studied

  • Dental Implantation
  • Missing Teeth
  • Periodontitis, Adult
  • Mucositis

Keywords

  • Enamel Matrix Derivatives
  • EMD
  • Keratinized mucosa width
  • Mucosal thickness
04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability of subject to understand and the willingness to sign a written document.
  2. Males and females; Age 18 to 89 years old
  3. Require second stage implant uncovering
  4. In either the maxillary or mandibular arch
  5. Has consistent transportation for all clinical and study visits

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy, or those planning to become pregnant
  2. Allergy or any medical issue using EMD
  3. Non-English speaking
  4. Patients on anticoagulants
  5. Patients who object to the use of animal products
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Group 1: Experimental Group using EMD

    During implant uncovering the experimental group will receive EMD under the buccal flap

    Device: Enamel Matrix Derivative

  • No intervention
    Group 2: Control Group

    No EMD is administered under the buccal flap during suturing

Interventions

  • DeviceEnamel Matrix Derivative

    EMD is an FDA approved medical device used in periodontal procedures since 1996. It has been shown to enhance soft and hard tissue healing, increased root coverage and aid in periodontal regeneration. It's use as an adjunct during implant uncovering may increase peri-implant mucosal thickness.

    Also known as: EMD

06

What researchers measure

Primary outcomes

  1. Mucosal Thickness

    Mucosal thickness at 1 and 5mm below the free gingival margin will be measured

    Time frame: One month and 3 months

  2. Change in Keratinized mucosal width

    measurement of keratinized mucosal width at one and three months after surgical uncovering of the dental implant

    Time frame: One month and 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The PI will ensure all mechanisms used to share data will include proper plans and safeguards for the protection of privacy, confidentiality, and security for data dissemination and reuse (e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant). Plans for archiving and long-term preservation of the data will be implemented as appropriate.

Supporting information: Study protocol, Statistical analysis plan

Time frame: At the conclusion of the study after data analysis is complete and the research is published in a peer reviewed journal

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2027, 25 months after the start.

Of 89 non-industry interventional studies with no phase under Chronic Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 24. This study's planned 25 months is above that.

Counting every sponsor, half of 90 studies reached it within 15 months; a quarter within 10 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 8, 2025
StartActual
Aug 31, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07053969
Responsible party
Angela Palaiologou-Gallis, DDS, MS (Professor, The University of Texas Health Science Center at San Antonio) — Principal investigator
First posted
Jul 8, 2025
Start date
Aug 31, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 12, 2025

Study contacts

Angela Palaiologou-Gallis, DDS
Contact
PalaiologouA@uthscsa.edu
210-450-3715
Angela Palaiologou-Gallis, DDS
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion